Pharmacokinetics and pharmacogenomics of cyclophosphamide in Rhabdomyosarcoma patients الحرائك الدوائية وعلم الأدوية الدوائي للسيكلوفوسفاميد في مرضى ساركومة العضلية // GP // DR.Rania Mohamed Labib // TA. Salma Wagih (2017-2018)
Material type: TextSeries: PHARMACY DISTINGUISHED PROJECTS 2018Publication details: Giza : MSA 2018Description: 77 P. 30 CMSubject(s): DDC classification:- 615
Item type | Current library | Call number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|
Distinguished Graduation Projects | Centeral Library Soft Copy located on library Cataloge | GP33PH2018CL.Pharmacy (Browse shelf(Opens below)) | Available | 81954 |
Pharmacy-Clinical Pharmacy
renewing
and asymmetric division that differentiate inside the body into
for example , Somatic cells. Stem cell is possible to identify two large
potential application fields of stem cells in diabetes mellitus: The
reconstruction of β cell mass, and helps in the treatment of complications.
Our target, find the mechanisms responsible for the effectiveness of bone
marrow-derived mesnchymal stem cells in the suppression of DM Type 1.
Experimental design: Eighteen male Albino Wistar rats divided into three
groups , each Group having Six Rat Group I normal not diabetic and not
suffering from any biochemical disorder, Group II Rats which are STZinduced
diabetes group, Group III will be the Mesnchymal stem cells
treated group MSCs (1×105 cells/rat) injected via tail veins in rats with
STZ-induced diabetes. Blood glucose was measured spectrophotometry,
Interleukin 6 and GLUT4 were measured by Elisa, insulin genes 1 and
insulin genes 2 were measured by Real-time PCR. Insulin genes 1, insulin
genes 2 and GLUT4 levels were significantly elevated in treated group
compared to diabetic group (1). Interleukin 6 and blood glucose levels
were significantly decreased in treated group compared to diabetic group.
Mesnchymal stem cells may play an important role in treatment of T1DM
There are no comments on this title.